The goal of Project 1.2 is to study the role of the chromatin remodeling complex BAF in the transcriptional repression of HIV and in the establishment of latency. We have observed that the chromatin remodeling complex BAF is necessary for the positioning of a single repressive nucleosome (nuc-1) downstream of the HIV transcriptional start site. Inhibition of BAF by selective knockdown of its subunits induces the expression of latent HIV in the J-LAT system. The hypothesis of Project 1.2 is that the BAF chromatin remodeling complex plays a critical role in the maintenance of HIV latency and that interfering with BAF function represents a new therapeutic target for reactivation of latent HIV.
Our aims i n this proposal are: 1. To determine the role of BAF chromatin remodeling complexes on the HIV promoter. The BAF complex, distinguished from the PBAF complex by a unique subunit (BAF250), plays an important role in the repression of basal HIV transcription. We will use chromatin immunoprecipitation to validate the presence of BAF subunits at the repressed HIV promoter and test the role of shRNAs specific for BAF subunits in HIV transcription. We will study the molecular mechanism of recruitment of BAF to the HIV promoter.
Aim 2. To study the role of the BAF complex in HIV latency in primary lymphoid cells. We will collaborate with other members of the Collaboratory (Planelles, Karn, Greene) to define the role of the BAF complex in HIV latency in primary lymphoid cells. We will also explore the biology of the BAF complex in primary lymphoid cells by (1) examining expression of its subunits (mRNA and protein) in resting and activated T cells, (2) knocking down specific subunits and examining patterns of global and HIV gene expression in resting and acti Aim 3. To validate the BAF complex as a therapeutic target for l/E therapy. We will explore BAF as a target for l/E therapy. We will use shRNA or slRNA against different BAF subunits and test their ability to reactivate latent HIV in primary lymphoid model systems for HIV latency and explore possible synergies between l/fe agents and selective BAF subunit knockdown. We will focus this analysis on existing agents, such as SAHA, prostratin and 5-azadeoxycyfidine, and on newer l/E agents developed in this Collaboratory.

Public Health Relevance

Understanding of HIV latency in molecular details represents the first and critical step in generating novel therapies to eliminate the pool of latently-infected cells from HIV-infected patients. We have identified a previously unrecognized cellular complex, called BAF, that plays a critical role in HIV transcriptional repression. These experiments will explore the biological role of the BAF complex in normal lymphocyte biology and in HIV latency and validate the BAF complex as a possible drug target in l/E therapy.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Honeycutt, Jenna B; Sheridan, Patricia A; Matsushima, Glenn K et al. (2015) Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol 21:301-9
King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5
Manson McManamy, Mary E; Hakre, Shweta; Verdin, Eric M et al. (2014) Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother 23:145-9
Duverger, Alexandra; Wolschendorf, Frank; Anderson, Joshua C et al. (2014) Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 88:364-76
Spivak, Adam M; Andrade, Adriana; Eisele, Evelyn et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58:883-90
Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872
Abreu, Celina M; Price, Sarah L; Shirk, Erin N et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257
Archin, Nancie M; Margolis, David M (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35
Liu, Pingyang; Xiang, Yanhui; Fujinaga, Koh et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25
Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46

Showing the most recent 10 out of 77 publications